Get the Stockscreener App
12.29
0.41%
0.05
After Hours:
12.23
-0.06
-0.49%
Stoke Therapeutics Inc stock is traded at $12.29, with a volume of 822.03K.
It is up +0.41% in the last 24 hours and down -15.53% over the past month.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
See More
Previous Close:
$12.24
Open:
$12.2
24h Volume:
822.03K
Relative Volume:
1.46
Market Cap:
$647.04M
Revenue:
$8.78M
Net Income/Loss:
$-104.70M
P/E Ratio:
-4.8577
EPS:
-2.53
Net Cash Flow:
$-82.68M
1W Performance:
-7.39%
1M Performance:
-15.53%
6M Performance:
-8.96%
1Y Performance:
+211.93%
1-Day Range:
$11.80
$12.46
1-Week Range:
$11.80
$13.25
52-Week Range:
$3.35
$17.58
Stoke Therapeutics Inc Stock (STOK) Company Profile
Name
Stoke Therapeutics Inc
Sector
Industry
Phone
781-430-8200
Address
45 WIGGINS AVENUE, BEDFORD, MA
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-01-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-26-23 | Resumed | Canaccord Genuity | Buy |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Oct-24-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-31-22 | Initiated | Jefferies | Buy |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Nov-22-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-21 | Initiated | UBS | Neutral |
| May-10-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Dec-11-20 | Reiterated | Needham | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Sep-29-20 | Initiated | Needham | Buy |
| Dec-18-19 | Initiated | Wedbush | Outperform |
| Nov-12-19 | Initiated | BTIG Research | Buy |
| Oct-25-19 | Initiated | H.C. Wainwright | Buy |
| Jul-15-19 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Credit Suisse | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
View All
Stoke Therapeutics Inc Stock (STOK) Latest News
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Acquired by Marshall Wace LLP - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Lynx1 Capital Management LP Has $70.05 Million Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics Inc [STOK] 10% Owner makes an insider purchase of 1,937,500 shares worth 27.22 million. - Knox Daily
Stoke Therapeutics Inc (STOK) expanding its growth trajectory ahead - SETE News
Logos Global Management LP Invests $14.19 Million in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down After Insider Selling - MarketBeat
How did Stoke Therapeutics Inc (STOK) fare last session? - US Post News
Logos Global Management LP Invests $14.19 Million in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat
Trend Tracker for (STOK) - Stock Traders Daily
Recent Insider Activity Could Benefit Stoke Therapeutics Inc (STOK) - Knox Daily
Skorpios Trust sells $27.2 million of Stoke Therapeutics stock By Investing.com - Investing.com Canada
Skorpios Trust sells $27.2 million of Stoke Therapeutics stock - Investing.com
Skorpios Trust sells $27.2 million of Stoke Therapeutics stock - Investing.com India
Stoke Therapeutics (NASDAQ:STOK) Trading Down 4.7% - MarketBeat
Live updates as 'bad accident' blocks Stoke-on-Trent road - Stoke-on-Trent Live
Bradley Foster & Sargent Inc. CT Increases Stock Position in On Holding AG (NYSE:ONON) - Defense World
Bid to turn Stoke-on-Trent six-bed into children's home - Stoke-on-Trent Live
Stoke Therapeutics Inc (STOK) Stock: From Low to High in 52 Weeks - The InvestChronicle
Pèlach picks first Potters’ line-up - Stoke City
Stoke Therapeutics (NASDAQ:STOK) Sees Large Volume Increase - MarketBeat
Stoke Therapeutics Inc [STOK] Shares Jump Approximately 221.78% Over the Year - Knox Daily
Narcís Pèlach appointed as Stoke City manager - Rayo
Latest managerial appointment confirmed in the Championship - Yahoo Eurosport UK
Stoke City new manager latest as Narcis Pelach set for bet365 Stadium watching brief - Stoke-on-Trent Live
Tragedy as baby boy is found dead at home – with woman, 26, and man, 25, arrested for ‘murder’... - The Sun
What is the investor’s view on Stoke Therapeutics Inc (STOK)? - US Post News
Two arrested on suspicion of murdering Stoke-on-Trent baby - Stoke-on-Trent Live
Stoke Therapeutics Inc (STOK) receives an Outperform rating from TD Cowen - Knox Daily
Check out these key findings about Stoke Therapeutics Inc (STOK) - SETE News
STOK’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Learn to Evaluate (STOK) using the Charts - Stock Traders Daily
Financial Health Check: Examining Stoke Therapeutics Inc (STOK)’s Key Ratios - The Dwinnex
Despite shrinking by US$52m in the past week, Stoke Therapeutics (NASDAQ:STOK) shareholders are still up 175% over 1 year - Simply Wall St
Los Angeles Capital Management LLC Has $902,000 Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics (NASDAQ:STOK) Receives “Buy” Rating from HC Wainwright - Defense World
Stoke Therapeutics (NASDAQ:STOK) Shares Down 7.3% - MarketBeat
The Potential Rise in the Price of Stoke Therapeutics Inc (STOK) following insiders activity - Knox Daily
Stoke Therapeutics settles director pay dispute - Investing.com India
Stoke Therapeutics stock gets Buy rating on promising trial data By Investing.com - Investing.com Canada
HC Wainwright Reiterates "Buy" Rating for Stoke Therapeutics (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics stock gets Buy rating on promising trial data By Investing.com - Investing.com UK
Analyst bullish on Stoke Therapeutics stock following key epilepsy drug data - Investing.com
Stoke Therapeutics settles director pay dispute - Investing.com
Zorevunersen shows promise in Dravet syndrome treatment - Investing.com
Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome - Business Wire
Stoke Therapeutics (STOK) Stock Surges on Potential Genetic Treatment Breakthrough - Nasdaq
Stoke Therapeutics names Eric Olson as CBO - The Pharma Letter
Stoke Therapeutics Stock: The First Gene Therapy For Dravet Syndrome (NASDAQ:STOK) - Seeking Alpha
Adversity is less terrifying than hope: Stoke Therapeutics Inc (STOK) - SETE News
Ratio Examination: Stoke Therapeutics Inc (STOK)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Stoke Therapeutics Inc Stock (STOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):